Elanco Animal Health Incorporated (NYSE:ELAN) went down by -2.53% from its latest closing price compared to the recent 1-year high of $37.49. The company’s stock price has collected -7.48% of loss in the last five trading sessions. MarketWatch.com reported on 02/26/22 that Not enough babies? EV battery shortage? Dwindling water? There are ‘scarcity’ stock plays for all of it
Is It Worth Investing in Elanco Animal Health Incorporated (NYSE :ELAN) Right Now?
Plus, the 36-month beta value for ELAN is at 0.79. Opinions of the stock are interesting as 5 analysts out of 10 who provided ratings for Elanco Animal Health Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $34.14, which is $11.54 above the current price. ELAN currently public float of 454.52M and currently shorts hold a 3.28% ratio of that float. Today, the average trading volume of ELAN was 4.31M shares.
ELAN’s Market Performance
ELAN stocks went down by -7.48% for the week, with a monthly drop of -13.81% and a quarterly performance of -26.36%, while its annual performance rate touched -42.56%. The volatility ratio for the week stands at 4.25% while the volatility levels for the past 30 days are set at 3.75% for Elanco Animal Health Incorporated. The simple moving average for the period of the last 20 days is -13.17% for ELAN stocks with a simple moving average of -28.52% for the last 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with Morgan Stanley repeating the rating for ELAN by listing it as a “Overweight.” The predicted price for ELAN in the upcoming period, according to Morgan Stanley is $40 based on the research report published on November 18th of the previous year 2021.
Stifel, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $34, previously predicting the price at $37. The rating they have provided for ELAN stocks is “Hold” according to the report published on October 28th, 2021.
Credit Suisse gave a rating of “Outperform” to ELAN, setting the target price at $38 in the report published on August 05th of the previous year.
ELAN Trading at -16.66% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.57% of loss for the given period.
Volatility was left at 3.75%, however, over the last 30 days, the volatility rate increased by 4.25%, as shares sank -17.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.56% lower at present.
During the last 5 trading sessions, ELAN fell by -7.48%, which changed the moving average for the period of 200-days by -40.74% in comparison to the 20-day moving average, which settled at $22.86. In addition, Elanco Animal Health Incorporated saw -29.42% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ELAN starting from HOOVER R DAVID, who purchase 10,000 shares at the price of $23.33 back on May 20. After this action, HOOVER R DAVID now owns 125,000 shares of Elanco Animal Health Incorporated, valued at $233,269 using the latest closing price.
BILBREY JOHN P, the Director of Elanco Animal Health Incorporated, purchase 10,000 shares at $22.03 during a trade that took place back on May 11, which means that BILBREY JOHN P is holding 34,222 shares at $220,284 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- +6.34 for the present operating margin
- +43.55 for the gross margin
The net margin for Elanco Animal Health Incorporated stands at -9.91. Equity return is now at value -4.70, with -2.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.